EANS-Adhoc: Sartorius AG / Both divisions continue to grow | Group operating earnings rise around 34% | Growth forecast for 2010 reaffirmed; slightly higher profit guidance

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Figures for the First Nine Months of 2010

22.10.2010

In the first nine months, the order volume for the Sartorius Group
rose 11.8% (currency-adjusted: +9.0%) from EUR454.8 million a year
ago to EUR508.3 million. Sales revenue increased 8.5% (+5.9%) to
EUR482.3 million from EUR444.7 million a year earlier. The
Biotechnology Division received orders valued at EUR330.9 million, up
9.1% (+6.4%) from EUR303.4 million a year ago, and increased its
sales revenue by 7.0% (+4.6%) from EUR298.0 million to EUR318.8
million. In the Mechatronics Division, order volume jumped
considerably by 17.2% (+14.1%) to EUR177.4 million from EUR151.4
million a year earlier and sales revenue climbed 11.4% (+8.5%) to
EUR163.6 million from EUR146.8 million in the previous year.

Underlying EBITA — consolidated earnings before interest, taxes and
amortization and adjusted for extraordinary expenses of EUR3.3
million (prev. year: EUR24.7 million) — rose 34.1% to EUR58.9 from
EUR43.9 million a year ago. The respective margin increased from 9.9%
to 12.2%. The Biotechnology Division contributed an underlying EBITA
of EUR50.1 million, up from EUR46.3 million a year earlier, to this
result, which means its margin edged up from 15.5% to 15.7%. For the
Mechatronics Division, underlying EBITA surged to EUR8.8 million
following an operating loss of EUR2.4 million in the previous year.
Its respective earnings margin improved from -1.6% to 5.4%.

Excluding non-cash amortization and extraordinary expenses, the
relevant net profit after minority interest for the period totals
EUR26.4 million (prev. year: EUR13.9 mn); the respective earnings per
share are at EUR1.55, up from EUR0.81 a year ago.

For the Group as a whole, we reaffirm our sales forecast for the full
fiscal year of 2010 and slightly raise our profit guidance. Relative
to the year earlier, we expect sales revenue growth to be slightly
above 5% in constant currencies, and our operating EBITA margin to
improve by around 2.5 percentage points (earlier guidance: up one to
two percentage points). Furthermore, our anticipated target of
achieving a significantly positive operating cash flow remains
unchanged.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius,
will discuss the results with analysts and investors on Friday,
October 22, 2010, at 2:00 p.m. Central European Time in a webcast
teleconference. You may dial into the teleconference starting at 1:45
p.m. CET at the following numbers: Germany +49 (0)69 2222 2245;
France +33 (0)1 70 99 42 66; UK +44 (0)20 7138 0825; USA +1 212 444
0481. The dial-in code is as follows: 4240400 The webcast and
presentation can be viewed at www.sartorius.com.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Andreas Wiederhold

Team Leader Treasury & Investor Relations

Telefon: +49 (0)551 308-1668

E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade